74785-02-7

Basic information

• Product Name: 2-(BROMOMETHYL)BENZYL ALCOHOL, 95%
• Synonyms: 2-(Bromomethyl)benzenemethanol, 2-Hydroxymethylbenzylbromide;BenzeneMethanol, 2-(broMoMethyl)-;(2-(broMoMethyl)phenyl)Methanol;2-(BroMoMethyl)benzyl alcohol 95%
• CAS NO: 74785-02-7
• Molecular Formula: C₈H₉BrO
• Molecular Weight: 201.07
• Product Categories: Alcohols;Building Blocks;C7 to C8;Chemical Synthesis;Organic Building Blocks;Oxygen Compounds
• Mol File: 74785-02-7.mol

Chemical Properties

• Melting Point: 66-68 °C
• Boiling Point: 279.551°C at 760 mmHg
• Flash Point: 152.617°C
• Appearance: /
• Density: 1.515g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.599
• Storage Temp.: 2-8°C
• PKA: 14.18±0.10(Predicted)
• CAS DataBase Reference: 2-(BROMOMETHYL)BENZYL ALCOHOL, 95%(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(BROMOMETHYL)BENZYL ALCOHOL, 95%(74785-02-7)
• EPA Substance Registry System: 2-(BROMOMETHYL)BENZYL ALCOHOL, 95%(74785-02-7)

Safety Data

• Hazard Codes: C,N
• Statements: 22-34-43-50
• Safety Statements: 26-28-36/37/39-45-61
• RIDADR: UN 3261 8/PG 2
• WGK Germany: 3
• Hazardous Substances Data: 74785-02-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-(Bromomethyl)benzyl alcohol, 95% is used as a key reagent for the synthesis of complex molecules. Its unique structure allows for the creation of a wide range of chemical products, making it valuable in both research and industrial settings.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-(Bromomethyl)benzyl alcohol, 95% is used as an intermediate in the production of various drugs. Its ability to form complex molecules makes it a valuable component in the development of new medications.
Used in Chemical Research:
2-(Bromomethyl)benzyl alcohol, 95% is utilized as a research tool in chemical laboratories. Its properties and reactivity are studied to understand the underlying mechanisms of various chemical reactions, contributing to the advancement of scientific knowledge.
Used in Material Science:
In the field of material science, 2-(Bromomethyl)benzyl alcohol, 95% is employed in the development of new materials with specific properties. Its versatility in forming complex structures makes it a useful component in the creation of innovative materials for various applications.

InChI:InChI=1/C8H9BrO/c9-5-7-3-1-2-4-8(7)6-10/h1-4,10H,5-6H2

Upstream product

• 612-14-6 phthalyl alcohol 
• 1634-04-4 tert-butyl methyl ether 
• 558-13-4 carbon tetrabromide 
• 85-44-9 phthalic anhydride 
• 88-99-3 benzene-1,2-dicarboxylic acid 
• 643-79-8 o-phthalic dicarboxaldehyde 
• 7115-89-1 2-(bromomethyl)benzoic acid 

Downstream Products

• 344339-67-9 2-<2-(hydroxymethyl)-phenylmethylthio>-1,3-benzoxazole 
• 835-78-9 [2-(2-phenylethyl)phenyl]methanol 
• 251961-48-5 2-(furfuryloxymethyl)benzyl alcohol 
• 849417-33-0 bromo[2-(hydroxymethyl-κO)benzyl-κC(1α)](triphenylphosphine)palladium 
• 213039-60-2 2,10-dihydroxy-6-[(2-(hydroxymethyl)benzyl)amino]-13-(β-D-glucopyranosyl)-12,13-dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione 
• 897388-19-1 (2-(but-3-yn-1-yl)phenyl)methanol 
• 148671-87-8 1-(bromomethyl)-2-<<<(1,1-dimethylethyl)dimethylsilyl>oxy>methyl>benzene 

Relevant articles and documents

Low-valent dialkoxytitanium(ii): a useful tool for the synthesis of functionalized seven-membered ring compounds

Herein, we describe unprecedented access to all-carbon or heterocyclic seven-membered ring frameworks from 1,8-ene-ynes promoted by inexpensive low-valent titanium(ii) species, readily available from Ti(OiPr)4and Grignard reagent. A broad range of cycloheptane, azepane or oxepane derivatives has been obtained (19 examples) with moderate to good yields and an excellent selectivity (up to 95/5 d.r.).

Novel substituted N-benzyl(oxotriazinoindole) inhibitors of aldose reductase exploiting ALR2 unoccupied interactive pocket

Recently we have developed novel oxotriazinoindole inhibitors (OTIs) of aldose reductase (ALR2), characterized by high efficacy and selectivity. Herein we describe novel OTI derivatives design of which is based on implementation of additional intermolecular interactions within an unoccupied pocket of the ALR2 enzyme. Four novel derivatives, OTI-(7–10), of the previously developed N-benzyl(oxotriazinoindole) inhibitor OTI-6 were synthetized and screened. All of them revealed 2 to 6 times higher ALR2 inhibitory efficacy when compared to their non-substituted lead compound OTI-6. Moreover, the most efficient ALR2 inhibitor OTI-7 (IC50 = 76 nM) possesses remarkably high inhibition selectivity (SF ≥ 1300) in relation to structurally related aldehyde reductase (ALR1). Derivatives OTI-(8–10) bearing the substituents –CONH2, –COOH and –CH2OH, possess 2–3 times lower inhibitory efficacy compared to OTI-7, but better than the reference inhibitor OTI-6. Desolvation penalty is suggested as a possible factor responsible for the drop in ALR2 inhibitory efficacy observed for derivatives OTI-(8–10) in comparison to OTI-7.

Enantioselective Synthesis of Indolines, Benzodihydrothiophenes, and Indanes by C?H Insertion of Donor/Donor Carbenes

We employ a single catalyst/oxidant system to enable the asymmetric syntheses of indolines, benzodihydrothiophenes, and indanes by C?H insertion of donor/donor carbenes. This methodology enables the rapid construction of densely substituted five-membered rings that form the core of many drug targets and natural products. Furthermore, oxidation of hydrazones to the corresponding diazo compounds proceeds in situ, enabling a relatively facile one- or two-pot protocol in which isolation of potentially explosive diazo alkanes is avoided. Regioselectivity studies were performed to determine the impact of sterics and electronics in donor/donor metal carbene C?H insertions to form indolines. This methodology was applied to a variety of substrates in high yield, diastereomeric, and enantiomeric ratios and to the synthesis of a patented indane estrogen receptor agonist with anti-cancer activity.

POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS

The invention features polynucleotide constructs containing one or more components (i) containing a disulfide linkage, where each of the one or more components is attached to an internudeotide bridging group or a terminal group of the polynucleotide construct, and each of the one or more components (i) contains one or more bulky groups proximal to the disulfide group. The invention also features polynucleotide constructs containing one or more components (i) containing a disulfide linkage, where each of the one or more components (i) is attached to an internudeotide bridging group or a terminal group of the polynucleotide construct, and each of the one or more components (i) contains at least 4 atoms in a chain between the disulfide linkage and the phosphorus atom of the internudeotide bridging group or the terminal group; and where the chain does not contain a phosphate, an amide, an ester, or an alkenylene. The invention also features methods of delivering a polynucleotide to a cell using the polynucleotide constructs of the invention.

POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS

The invention features a hybridized polynucleotide construct containing a passenger strand, a guide strand loadable into a RISC complex, and (i) a 3'-terminal or an internucleotide non-bioreversible group in the guide strand; or (ii) a 5'-terminal, a 3'-terminal, or an internucleotide non-bioreversible group in the passenger strand, and a 5'-terminal, a 3'-terminal, or an internucleotide disulfide bioreversible group in the guide strand or the passenger strand. The invention also features methods of delivering a polynucleotide to a cell using the hybridized polynucleotide construct. The invention further features methods of reducing the expression of a polypeptide in a cell using the hybridized polynucleotide construct.

Unprecedented synthesis of aza-bridged benzodioxepine derivatives through a tandem Rh(ii)-catalyzed 1,3-rearrangement/[3+2] cycloaddition of carbonyltriazoles

Rh(ii)-catalyzed novel tandem intramolecular cycloisomerizations of aldehydes or ketones with 1-sulfonyl 1,2,3-triazoles have been disclosed, providing a facile protocol to access a series of functionalized aza-bridged benzodioxepine heterocycles.

Tripodal tris-tacn and tris-dpa platforms for assembling phosphate-templated trimetallic centers

Multidentate tripodal ligands, N(CH2-m-C6H 4-CH2tacn)3 (L1) and N(CH2-o-C 6H4-CH2N(CH2py)2) 3 (L2), have been devised for assembling high-nuclearity metal clusters. By using the same tripodal platform with different ligand appendages, either triazacyclononanes or dipicolylamines, and functionalizing either the ortho or the meta positions on the tris(xylyl) linker arms, discrete trimetal phosphate units of relevance to phosphate-metabolizing trimetallic centers in biology were prepared. Four such compounds, [(CuIICl) 3(HPO4)L1](PF6) (1), [(CuIICl) 3(HAsO4)L1](PF6) (2), Na2[Mn III6MnII2(H2O) 2(HPO4)6(PO4)4(L1) 2] (3), and [CoII3(H2PO 4)Cl2(MeCN)L2](PF6)3 (4), all containing three metal centers bound to a central phosphate or arsenate unit bridging oxygen atoms, have been synthesized and structurally characterized. These results demonstrate the propensity of this novel tripodal ligand platform, in the presence of phosphate or arsenate, to assemble {M3(EO 4)} units and thus structurally mimic trimetallic active sites of proteins involved in phosphate metabolism. Reactivity studies reveal that the tricopper complex 1 is more efficient than monocopper analogues in catalyzing the hydrolysis of 4-nitrophenyl phosphate.

ENDOTHELIN RECEPTOR ANTAGONISTS

Novel pyridines, pyrimidines, pyrazines, pyridazines and triazines, pharmaceutical compositions containing these compounds and their use as endothelin receptor antagonists are described.

ENDOTHELIN RECEPTOR ANTAGONISTS

Novel indane and indene derivatives are described which are endothelin receptor antagonists.

Catalytic intramolecular addition of metal carbenes to remote furans

(formula presented) Diazo esters and diazo ketones linked to a furan undergo catalytic intramolecular addition of an intermediate metal carbene to the remote furan to form diendiones with ring sizes up to 17. Regioselectivity is catalyst dependent with addition to either the more or less substituted double bond. The high product yields and absence of need for high dilution suggest that this methodology is general for macrocycle preparations.